Castres, France

Robert Letienne

USPTO Granted Patents = 3 


 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2011-2013

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovations of Robert Letienne

Introduction

Robert Letienne is a notable inventor based in Castres, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that serve as antagonists for protease-activated receptor-1 (PAR-1). With a total of 3 patents to his name, Letienne's work is recognized for its potential impact on the treatment of thrombosis.

Latest Patents

Letienne's latest patents include innovative compounds known as cinnamoyl-piperazine derivatives. These compounds are designed to act as PAR-1 antagonists, which are particularly useful in the treatment of thrombosis. The present invention relates to compounds of general formula (I), which have shown promise in medical applications.

Career Highlights

Throughout his career, Robert Letienne has been associated with Pierre Fabre Medicament, a company known for its commitment to research and development in the pharmaceutical sector. His work has contributed to advancements in therapeutic options for patients suffering from thrombotic conditions.

Collaborations

Letienne has collaborated with esteemed colleagues such as Michel Perez and Marie Lamothe. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to the development of groundbreaking medical solutions.

Conclusion

Robert Letienne's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his role as a significant inventor. His work continues to pave the way for advancements in medical treatments, particularly in the area of thrombosis.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…